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Abstract: Addiction involves complex physiological processes, and is characterised not only by broad phenotypic and behavioural traits, 
but also by ongoing molecular and cellular adaptations. In recent years, increasingly effective and novel techniques have been developed 
to unravel the molecular implications of addiction. Increasing evidence has supported a contribution of the nuclear transcription factor 
CREB in the development of addiction, both in contribution to phenotype and expression in brain regions critical to various aspects of 
drug-seeking behaviour and drug reward. Abstracting from this, models have exploited these data by removing the CREB gene from the 
developing or developed mouse, to crucially determine its impact upon addiction-related processes. More recent models, however, hold 
greater promise in unveiling the contribution of CREB to disorders such as addiction. 
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INTRODUCTION 
  The compulsive or uncontrolled use of a drug is often used to 
define addiction [57], which develops after repeated drug exposure, 
despite severe adverse consequences [58, 79]. It is the progression 
from recreational or controlled use of a drug to this unbalanced, 
compulsive state that is a distinguishing hallmark of addiction. The 
underlying pathology of addiction has been partly described by 
different theories, and prominently includes the opponent process 
theory [57, 109], an incentive salience model explaining excessive 
drug wanting [9, 53, 97], and the development of learned adapta-
tions, describing drug-memory associations [22]. Unifying these 
theories is a compelling, underlying proposal that the development 
of addiction relates to long term drug-induced neural adpatations, 
some of which may be manifest following even an acute drug expo-
sure. Such adaptations are observed through behavioural testing and 
include dependence (where compensation for drug effects beget 
withdrawal-symptoms subsequent to cessation of drug intake) and 
tolerance (a condition where drug effects diminish subsequent to 
ongoing drug exposure [55]). In contrast, sensitization represents a 
phenomenon involving enhanced drug response, typically subse-
quent to a cycle of drug exposure and abstinence [9, 22, 53, 97]. 
Moreover, the contextual association between drug and environ-
ment dramatically impacts upon the development and expression of 
sensitization [9, 97]. It should be noted, however, that physical 
dependence upon a substance is not a necessary precondition for 
addiction. In sum, addiction has been likened to an abberent form of 
learning, involving stable changes responsible for long-term behav-
ioural plasticity, manifesting as changes in behavioural response to 
acute or repeated drug exposure [33, 52, 104]. 
  A recurring issue associated with rehabilitated drug addicts is 
their ongoing potential to relapse, which is not fully ameliorated 
either by long periods of abstinence nor psychological treatments. 
This suggests that molecular changes in the brain have been instan-
tiated by a nominal period of drug exposure, not reversible by drug 
abstinence alone. Berke and Hyman [8] describe this process as a 
drug-induced usurpation of molecular mechanisms commonly in-
volved with associative learning, which drive compulsive drug 
abuse and propensity to relapse. Whether molecular or synaptic 
alterations in neuronal communication or function are a homeo-
static adjustment to drug insult or longer term plasticities contribut-
ing toward learned behaviours is not clear [8]. Nevertheless, the end 
result is a complex neural change for which we have so far failed to 
fully characterise the substrates involved and the specific role that 
they play.  
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  Shaywitz and Greenberg [106] make the point that, “Under-
standing of the mechanisms by which extracellular stimuli induce 
changes in gene expression is critical for understanding how cells 
can adapt to environmental cues.” Thus, in order to comprehend 
the technical and complex nature of the behavioural response asso-
ciated with drug abuse, the apposition of molecular evidence is 
required to help explain these changes at the cellular level and ulti-
mately, neural systems level. An immediate imperative driving 
current addiction research is the identification of a molecular target 
which can mediate long term neuronal lability. FosB [73, 82] and 
PSD-95 [124] alike have been recently identified as leading sub-
strates in this regard, with modified expression observed up to four 
and eight weeks following drug stimulus respectively. Moreover, 
chronic cocaine has been associated with increases in dendritic 
spine density in the NAcc, but these changes do not appear long-
lived enough to correspond with prolonged behavioural changes 
[81]. Accordingly therefore, other potential molecular targets impli-
cated in the development of addiction are worthy of examination. 
  It is widely believed that changes in gene expression underlie 
neural adaptations following exposure to drugs of abuse [28]. A key 
mechanism for regulating gene expression is through nuclear induc-
tion of the transcription factor CREB, implicated also in various 
affective states, learning and memory. As indicated in Mayr and 
Montminy [71], “At a mechanistic level, CREB is perhaps one of 
the best understood phosphorylation-dependent transcription fac-
tors. By comparison, relatively little is known about the physiologi-
cal role of this protein in different systems.” This challenge has 
fallen to, and been taken up by, a surfeit of behavioural, molecular 
and neuropharmacological investigations, and slowly, a complex 
picture is emerging. A key challenge for investigators, however, is 
the advance from a discrete molecular and neuronal synthesis to 
that of a systems level, as thoroughly emphasised by Nestler [79-
81]. Indeed, as Greengard [40] notes, with one hundred billion neu-
rons in the brain, and each sharing approximately one thousand 
reciprocal connections, deducing the collective afferent and efferent 
neuronal colloquy is a formidable task. Appreciating the inter- and 
intra-communications of discrete neural systems comes from under-
standing their function at a molecular level.  
  Here, we examine recent evidence supporting the contribution 
of CREB as a key molecular mechanism in the development of 
addiction. Further to this, a variety of models are discussed, which 
have resolved to restrict or delete the expression of this transcrip-
tion factor, attempt to explain the role CREB has played. Finally, 
we comment upon more recent and effective techniques for the 
restriction of CREB deletion in the adult brain.  
INVOLVEMENT OF CREB IN ADDICTION 
  The current state of addiction neurobiology is charactersing a 
molecular substrate which can partially explain the ongoing behav-
ioural changes wrought by addiction, however, this was not always The Nuclear Transcription Factor CREB  Current Neuropharmacology, 2007, Vol. 5, No. 3    203
the case. Earlier work sought to determine which regions of the 
brain were critically involved in addiction, and subsequently, what 
pathways were consistently activated. An extensive body of data 
has now thoroughly demonstrated that the activation of the meso-
corticolimbic dopamine system is a key mechanism inovolved in 
drug reward and reinforcement, a system which involves dopa-
minergic projections from the mesencephalon that synapse onto the 
nucleus accumbens, striatum, aymgdala and prefrontal cortex. Stud-
ies employing both lesioning experiments [27, 30, 37, 45, 48] and 
pharmacological manipulations [31, 103, 113] have collectively 
demonstrated the importance of such structures including the pre-
frontal cortex (PFC), nucleus accumbens (NAcc), dorsal striatum, 
hippocampus and amygdaloid nuclei in relation to drug-seeking 
behaviour and drug-induced plasticity. The activity of this network, 
and the interface of this network with other structures (e.g. hypo-
thalamus and brain stem nuclei) is critical to long lasting molecular 
changes driving relapse.  
  Dopamine receptors are G-protein coupled receptors (GPCRs) 
which involve the regulation of adenylate cyclase (AC), generating 
the second messenger cyclic AMP (cAMP) from ATP. Indeed, it 
was as early as 1987 that cAMP was found to enhance CREB acti-
vation in PC-12 (pheochromocytoma cell line) nuclear extracts 
[77]. This discovery heralded the identification of a molecular tar-
get regulating gene expression which could potentially explain the 
central development of addiction. Subsequent study investigated 
other intracellular signal transduction pathways culminating in the 
activation of CREB, as well as various paradigms of drug abuse 
which activated this key molecular substrate. As corticostriatal and 
corticotegmental glutamatergic efferents are also implicated in drug 
reward, calcium-activated CREB was examined, and the field of 
study burgeoned. Some of the intracellular signalling transduction 
pathways implicated in the activation of CREB are demonstrated in 
Fig. (1), and include G-protein, ion channel and growth factor drug 
receptor targets. These pathways often involve the association of a 
drug ligand with its respective receptor target, and a kinase phos-
phorylation cascade culminating in the translocation of a second 
messenger into the nucleus, phosphorylating CREB at Ser
133
(pCREB). CREB is a member of a basic leucine zipper (bZIP) 
CREB/ATF-1 sub-family which includes members CREM (cAMP 
Responsive Element Modulatory protein) and ATF-1 (Activating 
Transcription Factor 1), both which bear high bZIP region sequence 
homology [106], and can bind as homo- or hetero-dimers with these 
members to the canonical cAMP Responsive Element (CRE) con-
sensus sequence via the leucine zipper in the promoter regions of 
target genes [11, 22, 61]. The CREB/CREB homodimer exhibits a 
half-life of 10-20 minutes [106]. Subsequent to phosphorylation at 
Ser
133, CRE-bound CREB can exert its influence upon target gene 
transcription and interact with promoter-bound cofactors. The lit-
erature has so far less effectively studied the contribution of family 
members CREM and ATF, or their various isoforms. 
EVIDENCE FOR CREB IN ADDICTION 
  An ever increasing body of evidence implicates the molecular 
actions of CREB in experimental paradigms related to addiction, a 
small number of which are demonstrated in Table 1. More recently, 
studies have examined the expression of pCREB following a vari-
ety of drugs of abuse employing in vivo models, off a background 
of over fifteen years of in vitro work with cell cultures. Largely, 
these studies have provided a conflicting array of results regarding 
positive and negative regulation of pCREB expression, with diver-
gences particulary noted across brain regions examined and tempo-
ral follow-up, as well as the period of administration including 
acute, chronic and subsequent to precipitated withdrawal. Many of 
these details are demonstrated in Table 1, in particular the delay to 
neurochemical analysis as well as treatment paradigm. 
Fig. (1). CREB signalling pathways. 
The schematic provides a brief overview of some major intracellular transduction signalling cascades involved in the activation of CREB by 
phosphorylation at Ser
133. Synaptic plasticity associated with addiction results from long-term cellular change derived from activation of 
CREB. Prominent examples of neurochemicals involved in addiction and their complementary receptors, are subsequently indicated. Gs: 
Adenosine A1/2, Dopamine D1/5; Gi/o: Dopamine D2/3/4, GABA-B; Gq/11: Glutamate (metabotropic) mGluR1/5; Ion Channels: Gluta-
mate NMDA/AMPA GluR1R/Kai-nate, L-Type VGCC; Growth Factor Receptors: EGF/NGF/BDNF TrkA, TrkB. Abbreviations: AC, 
adenylate cyclase; CalM, calmo-dulin; CaMK, calcium/calmodulin-dependent protein kinase; ERK 1/2, extracellular signal regulated kinase; 
MEK, MAPK and ERK kinase; PDE, phosphodiesterase; PLC, phospholipase C; PI3K, phosphoinositide-3 kinase; RSK, ribosomal-S6 
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 Almost  unfailingly, natural or precipitated withdrawal from 
drugs of abuse leads to a dramatic alteration in the expression of 
nuclear pCREB. Whilst the positive or negative nature of this im-
pact appears dependent upon the brain region studied, substantial 
pCREB changes have been observed following withdrawal from 
ethanol (EtOH) [84, 86, 88], morphine [23, 41], psychostimulants 
(including: amphetamine [46], cocaine [60] and methamphetamine 
[75], MDMA [70]) and nicotine [15, 85, 94]. This may suggest a 
regional sensitization in the pCREB response, elsewhere deputised 
through CRE activation reporters [3, 7, 14, 105], providing a mo-
lecular stimulus for relapse behaviour. Together these data suggest 
that repeated exposure to multiple drugs of abuse may produce 
sustained activation of intracellular transcription factors, resulting 
in the persistent and altered expression of functionally important 
gene products that may underlie the onset and maintenance of ad-
diction [36]. Clearly, a role for pCREB in this process is beyond 
doubt, and it remains to us as investigators to fully unlock and char-
acterise the methods and higher-level mechanics behind its action.  
THE DIVIDE BETWEEN CREB AND pCREB 
  Of those papers listed in Table 1 and elsewhere [125] which 
examined the impact of drug upon nuclear CREB expression, few 
of them demonstrated some corresponding shift in its expression 
levels [74, 85, 94]. In contrast, substantial variation in the expres-
sion pattern of its activated form, pCREB, was observed. Such ob-
servations were made consistently across discrete brain regions and 
other physiologically significant organs, revealing little correlation 
between CREB and pCREB levels. It may be that CREB levels are 
more invariant to change given the necessary involvement gene 
transcription, translation and subsequent post-translational modifi-
cation events, whereas, the changes in pCREB levels are merely 
indicative of protein kinase action.  
  A good reason for differential CREB or pCREB expression is 
that different central nuclei and cell populations offer various gene 
targets for these transcription factors, each likely exhibiting their 
own sensitivites to changes in the CREB transcription factor to 
induce gene transcription. Mayr and Montminy [71] tabulate some 
105 genes with functional CRE motifs identified in the literature, 
half containing a single CGTA motif. One quarter of these CRE-
bearing genes function in cellular metabolism, and the vast majority 
in some way could directly contribute to neural adaptation or syn-
aptic plasticity following drug insult. Whilst a small number of 
CRE-bearing genes endogenous to the brain have been identifed in 
the literature, this observation underlies the likelihood that CREB is 
Table 1.  CREB Involvement in Addiction 
STUDY  DRUG & TREATMENT SCHEDULE  DELAY TO NEURO- CHEMICAL 
ANALYSIS^ 
pCREB EXPRESSION EFFECT 
[76]  EtOH 
Chronic, drinking 
0 hour (on final access day)  Decreased in NAcc shell, no change in NAcc core, FC nor CeA 
[84]  EtOH 
Chronic, liquid-diet; Withdrawal 
0 hour (on final access day) or 24 hour 
(withdrawal) 
Decreased in CG, no change in cortex*; Change in all regions to 
withdrawal 
[86]  EtOH 
Chronic, liquid-diet; Withdrawal 
0 hour (on final access day) or 24 hour 
(withdrawal) 
No changes in CeA, MeA, nor BLA; Change in all regions to with-
drawal  
[122]  EtOH 
Acute, ip; Chronic, liquid-diet 
15 minutes, 1 & 6 hour: acute;  
0 hour: chronic † 
Increase in cerebellum (acute, max at 15 min) or no change (chronic) 
[123]  EtOH 
Acute, ip; Chronic, liquid-diet 
5, 15, 30 minutes: acute;  
30 minutes: chronic 
Increase (acute, max at 30 min) or decrease (chronic) in cerebellum 
[41]  Morphine 
Acute, sc; Chronic or precipitated with-
drawal, pellet 
1 hour: acute;  
24 hour: chronic 
Increase (withdrawal), decrease (acute) or no change (chronic) in LC 
[74]  Morphine chronic, sensitised, ip; withdrawal 
& challenge 
90 minutes: 3d & 14d withdrawal †  Decrease in NAcc and VP (3d and 14d withdrawal, following chal-
lenge) 
[44]  Nicotine 
Acute, repeated, ip 
0-6 hour  Increase in adrenal medulla (from 30 min) 
[54]  Nicotine 
Repeated, ip 
1 hour  Increase in adrenal medulla 
[85]  Nicotine 
Chronic, withdrawal, ip 
1 hour: chronic;  
18 hour: withdrawal 
Decrease in CG, ParC, PiriC, MeA and BLA (withdrawal) or no 
change (chronic); No change in FC nor CeA 
[94]  Nicotine 
Acute & chronic withdrawal 
1, 18 hour  Decrease in NAcc shell (chronic 18 hour withdrawal) or no change; 
no change in core 
[26]  Amphetamine 
Acute, chronic, sensitised, ip 
1 hour: acute & chronic;  
16 hour: chronic 
Increase in striatum (sensitised was lower than acute) 
[36]  Amphetamine 
Acute, ip 
15 minutes  Increase in striatum 
[56]  Amphetamine 
Acute, ip 
2 hour  Increase in striatum 
[111]  Amphetamine 
Acute, chronic, sensitised, ip 
2 hour  Increase in striatum (chronic, sensitised) 
[75]  Methamphetamine Chronic, sensitised, sc  3d or 14d withdrawal  No change in VTA (3d & 14d); Decreased in NAcc and VP (3d & 
14d); Increase (3d) or no change (14d) in FC 
^ = time animal was killed after last drug exposure; time periods at which pCREB expression was measured 
* = frontal cortex, piriform cortex, parietal cortex 
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likely to impact differently in various neural regions. In a recent 
review, Carlezon and colleagues [16] highlight that CREB gene 
promoter targets number in their thousands and that not all CRE 
motif containing genes are functional CREB targets. In their words, 
“the consequences of a change in CREB function, or in an up-
stream pathway, in various brain regions are [thus] likely to be 
multifaceted and difficult to predict a priori.” 
  Within the NAcc, for example, genes positively identified for 
upregulation by CREB include proenkephalin (Penk1), prodynor-
phin (Pdyn), and c-Fos (Fos) [2, 17, 72, 118], however, evidence 
supports a much broader extent of influence [71, 72], be it directly 
or indirectly via IEG induction. Psychostimulants have been shown 
to induce preprodynorphin mRNA in the NAcc through a CREB-
mediated mechanism, and subsequently, these data have been used 
to establish an increasing recognition for dynorphin in its contribu-
tion to the expression of sensitization [90]. Different CREB gene 
targets are identifed in differing central nuclei, although investi-
tagor bias means that often gene targets are not consistently exam-
ined across nuclei. For example, Olson and colleagues [83] only 
examined GluR1 and TH genes as they are both known to contrib-
ute to drug reward in the VTA, with similar practises concerning 
opioids in the NAcc [17, 93, 108].  
CONTROLLING CREB EXPRESSION: CONVENTIONAL 
MODELS  
  The collective in situ and immunoblotting data indicated that 
CREB and/or activated CREB are regulated by various drugs of 
abuse within brain regions implicated in addiction. These data 
raised the question as to the precise role for CREB in mediating 
addiction-related behaviours To this end, novel transgenic tech-
niques were employed to knockout CREB and observe functional 
implications. The most obvious beginning was deletion of the DNA 
binding domain and all of the leucine zipper on the Creb gene, pro-
ducing CREB-null mice (Creb
null) devoid of central and peripheral 
functional isoforms of CREB through inability to dimerise or bind 
to DNA (at the CRE site). Null mice were observed to have a re-
duced birth weight (70%) relative to wild type mice, were cyanotic, 
and died immediately after birth (perinatally) from respiratory dis-
tress (pulmonary atelectasis) [71]. The mutant also exhibited other 
developmental abnormalities and phenotype including a birth rate 
less than Mendelian frequency, hypoplasia/atrophy of the corpus 
callosum and anterior commissure, a markedly reduced thymic 
cellularity affecting all developmental stages of the -T cell line-
age, and upregulated CREM in the hippocampus and other fore-
brain regions; in contrast, wild type expression of CREM is pre-
dominantly restricted to neuroendocrine neurons [98]. The total 
deletion of all central and peripheral isoforms of CREB were, de-
spite the upregulation in CREM (which possibly allowed the mutant 
to reach parturition), the likely cause for these apparently diverse 
defects. Given the contribution of CREB to neuronal growth, plas-
ticity and survival mediated by the neurotrophins including NGF, 
BDNF and NT-3 [63, 99, 114, 121], the impact of total CREB dele-
tion was ubiquitious, substantially impairing normal organ and 
physiological development. It has been recently shown that mice 
with a null mutation for Creb restricted to central regions do not 
show the excessive apoptosis witnessed by peripheral Creb null 
mutation [63], driving subsequent studies into central-specific 
CREB recombination, discussed later. 
DISCOVERY OF A NOVEL CREB ISOFORM 
  An early attempt to create a CREB-null mutant led to the de-
velopment of the now widely recognised Creb1
 mutant. Hummler 
and colleagues [47] created mutant mice by embryonic stem cell 
homologous recombination, inserting a promoterless Neo construct 
into the second exon of the Creb1 gene, which harbours the first 
ATG codon [69]. They observed that the proportion of mutant mice 
surviving was down on expected Mendelian outcome, although 
adult mutants demonstrated a normal phenotype (measuring for 
ataxia/motor disorders/nociception/shock response) with no his-
tological or morphological deficits [13]. Blendy and colleagues [10] 
mused that the healthy disposition of mutants was puzzling because 
CRE-mediated gluconeogenic enzyme expression (critical for peri-
natal surivival) should be attenuated by the mutation, and that based 
on previous evidence of CREB in the pituitary, growth should be 
retarded. Indeed, while ATF-1 levels were unaffected in the mu-
tants, RNA isoforms of CREM were upregulated (including the 
activator (CREM) and repressor (CREM, CREM) isoforms, 
which lack an activator-specific exon), and a novel form of CREB, 
CREB-, was observed to be upregulated [115]. CREB- carried a 
molecular weight of 40kDa and was identical to CREB- (the 
prevalent CREB isoform) except for a deletion of 40 residues of the 
Q-domain; its upregulation was 6-fold in the brain and 4-fold in the 
liver, with upregulation also in the testes [10]. CREM isoforms, 
previously shown to be expressed in (or constrained to) neuroendo-
crine nuclei, now became expressed ubiquitously throughout the 
brain [10]. Such mutants have been described as carrying a hypo-
morphic CREB allele or as being haplodeficient in CREB [87], and 
a great deal of experimental work has been conducted using this 
model.  
ADDICTION STUDIES USING MICE HYPOMORPHIC FOR 
CREB
  The balance of studies examining the impact of CREB knock-
down in the context of addiction have done so with the CREB

paradigm, probably because the model does not require time-
consuming preparation and development, whilst still providing an 
interesting experimental subject. Such mutants do express higher 
than normal CREB- levels, although studies have suggested [47, 
66] and recently shown that total CREB activity is reduced ap-
proximately 90% throughout the brain (cortex, cerebellum, sub-
cortical nuclei) [115]. Clearly, the peripheral expression of CREB-
, though impaired, is enough to propagate required developmental 
homeostatic mechanisms in these mutants. The studies shown in 
Table 2 demonstrate a complex phenotype of this CREB knockout 
model. Numerous studies provide evidence that mutants have at-
tenuated behavioral response to morphine withdrawal [66, 112, 
115]. These mutants are basally more anxious than WT [87], which 
was demonstrated to impact upon EtOH (drug) preference rather 
than natural reward preference. Interestingly, whilst some studies 
demonstrate that cocaine and morphine earn a similar salience as 
well as exerting similar behavioural influence in mutants as wild 
types [59, 66, 112] others provide evidence to the contrary, or at 
least which hinders us in drawing any compelling conclusions [115, 
117]. Moreover, Walters and colleagues [116] recently demon-
strated that although 1mg/kg nicotine was rewarding to WT but not 
mutants, 2mg/kg nicotine elicited an aversive response in both mu-
tants and WT’s, underlying the difficulty and complexity associated 
with interpretation of these results.  
  Collectively, these data emphasise the differential and unpre-
dictable effect of diminished CREB throughout the CNS on behav-
iour and gene transcription [66, 87, 118], including various memory 
and learning conditions (for example, deficits observed in some but 
not all long term memory tests) [13, 34, 39]. No doubt complicating 
such results is the upregulation of CREM throughout the CNS so 
that it no longer distributes primarily in neuroendocrine-associated 
nuclei, as well as the upregulation in CREB- [10], affecting the 
consistent reporting of affective and cognitive deficits. Whist this 
model is a step toward ascertaining the contribution of CREB to 
addiction, it is inferior to recent spatiotemporal models where 
CREB deletion is total, and the subject’s system has little time or 
scope to compensate for the knockout. Given the problems encoun-
tered with the peripheral knockdown of CREB, various novel mod-
els have been employed to target central expression of CREB, and 
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CREB AND DOMINANT-NEGATIVE CREB OVEREX-
PRESSION USING HSV 
  One such model is herpes simplex virus (HSV)-mediated over-
expression of CREB in specific brain nuclei or, in order to gain a 
local knockdown of CREB, the dominant-negative isoform mCREB 
(mutant CREB). Mutant CREB (mCREB) contains a serine-to-
alanine substitution at position 133, eliminating the cAMP-depen-
dent protein kinase phosphorylation site but maintaining charge 
balance. Subsequently, whilst mCREB can still bind to cAMP re-
sponsive elements (CREs), it inhibits active CREB by occupying 
the CRE and preventing access by wild-type CREB and other CRE-
binding proteins [98, 106]. The HSV-(m)CREB system achieves 
maximal expression of virally-encoded transgenes by 24 hours 
post-injection, which persists for three to four days before dissipat-
ing to trace or zero expression by day seven post-injection [83]. A 
number of recent studies have examined the impact of HSV over-
expression of (m)CREB in discrete regions of the CNS upon pheno-
type, shown in Table 3. The balance of these studies have as a key 
endpoint the impact of (m)CREB overexpression upon the reward-
ing effects of cocaine or morphine [7, 17, 93], finding that CREB 
overexpression in the NAcc shell decreases drug reward whilst 
mCREB enhances drug reward, results that may also apply to natu-
ral rewards [7]. Such data suggest that immediately following drug 
intake, upregulation in accumbal CREB (or increased phosphoryla-
tion of CREB) may diminish the salience of further drug admini-
stration. This suggests a contribution to either early development of 
tolerance, or development of an inbuilt safety-mechanism which is 
activated as the body recovers from drug insult. Other findings 
using this system drive home the observation that regional CREB or 
mCREB overexpression has a markedly different impact upon ei-
ther reward [17, 83] and affective states measured through pheno-
typic traits of anxiety or depression [7, 24, 93], or of physical de-
pendence [42]. Using recombinant Sindbis pseudovirions to drive 
constitutively active or dominant negative CREB overexpression in 
the NAcc, Dong and colleagues [29] demonstrated a recovery or 
further decrement in MSN excitability, respectively, in a rat model 
of cocaine bingeing.  
  This model is conceptually appealling, and indeed, the overex-
pression of dominant negative (mCREB) allows investigators to 
deduce the impact of substantial CREB knockdown in specific 
brain nuclei. In contrast, numerous studies have suggested that al-
terations in CREB levels per se following cross-temporal drug 
abuse seem to occur unpredictably, if at all. A far more consistent 
expression marker is its phosphorylated or active from, pCREB, 
and the cogent point made by Walters and colleageus [118] applies, 
“Given that phosphorylated CREB (pCREB) is the transcriptionally 
active form of CREB and that a given stimulus might lead to the 
phosphorylation of only a few dozen molecules of CREB per cell, 
alterations in total CREB levels achieved by genetic manipulations 
might or might not lead to significant changes in pCREB depending 
on the original protein levels present”. In the balance of the HSV-
CREB overexpression studies, experiments are conducted 2-3 days 
post-injection. Given that CREB (or more accurately, pCREB) 
expression shows a distinct and no doubt critically relevant tempo-
ral regulation following drug abuse stimuli, we are hard pressed to 
guess at what sort of remodelling effects prolonged CREB exposure 
may implement in discrete neural regions. Moreover, this overex-
pression period is unlikely to complement anything wrought upon 
CREB or pCREB expression by pharmacological or stressor meth-
odology. Drugs of abuse alter pCREB levels directly through kinase 
pathways, and CREB levels indirectly through gene expression 
systems; however, viral (HSV) overexpression systems increase 
Table 2.  Characterisation of the CREB
 Model 
STUDY  DRUG EXPOSURE & CONDTION  CREB EXPRESSION EFFECT  PHENOTYPIC EFFECT 
[87]  EtOH solution (chronic ?);  
Sucrose solution (natural reward) 
EtOH (acute) 
Mutant p/CREB was decreased 40% through 
extended amygdala & cortex; Acute EtOH in-
creased pCREB in the CeA & MeA in WT & 
mutants 
Mutants had higher preference for EtOH but not su-
crose; Mutants were more anxious than WT; Acute 
EtOH was anxiolytic in WT & mutant 
[59]  Cocaine CPP model;  
Stress (FST) 
In cocaine-pretreated WT, stress challenge incre-
sed pCREB in NAcc, whereas cocaine challenge 
increased pCREB in amygdala and VTA 
Stress didn’t induce reinstatement in cocaine pre-treated
mutants, as it did in WT; Cocaine induced reinstate-
ment in cocaine-pretreated mutants and WT 
[39]  Fear conditioning (foot shock);  
Spatial learning (MWM); 
Mutants had impaired SR & LR cued and contextual 
fear conditioning response (associative-learning re-
sponse), but normal spatial learning/memory 
[34]  Fear conditioning (foot shock); 
Spatial learning / reference memory 
(MWM); LTP (CA1, DG) 
No deficits were observed retention of freezing memory
in mutants, nor LTP measures; essentially normal 
pheotype observed in spatial learning/memory test 
[112]  Morphine, cocaine & food CPP model; 
Naloxone-induced morphine with-
drawal 
Rewarding effects of morphine, cocaine & food were 
no different in mutants and WT; mutants had attenuated
behavioural response to naloxone-induced withdrawal 
[115]  Morphine (chronic);  
Morphine & cocaine CPP model 
Mutants had attenuated behavioural response to chronic
morphine withdrawal; Mutants had enhanced response 
to reinforcing properties of cocaine but not morphine in 
CPP paradigm; Mutants had enhanced sensitised loco-
motor behaviours to cocaine 
[66]  Morphine (acute, chronic); 
Naloxone-induced morphine with-
drawal 
Stress (?) 
Mutants had attenuated behavioural response to chronic
morphine naloxone-induced withdrawal; Mutants had 
similar acute morphine-induced analgesia, locomotor 
activity and behaviorual response to  stress as WT 
[117]  Morphine CPP model (low, high dose)    High dose morphine increased CPP reward and loco-
motor activity in mutants; Low dose morphine had 
decreased reward in mutants but unchanged locomotor 
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CREB directly, without altering pCREB levels directly through 
endogenously occuring systems. Subsequently, these results are 
somewhat difficult to interpret in regards of existing literature ex-
amining drugs of abuse in wild type mice given a differential 
method and time course in generating synaptic plasticity and neu-
roadapatation. Finally, whilst CREB is constitutively expressed in 
the nucleus, viral overexpression of CREB enters via the cytosol, 
suggestive of stochastic or unknown levels of trafficking into the 
nucleus to affect target CRE-binding and subsequent plasticity. 
Although the extent and kinetics of mCREB dimerisation (with 
CREB, CREM and ATF-1), CRE-DNA binding and subsequent 
dimer transcriptional activation potency is not fully known [65], 
HSV-mCREB overexpression appears to be a promising strategy in 
the ongoing elucidation of central CREB’s impact in the context of 
addiction studies. 
TETRACYCLINE-REGULATED TRANSACTIVATION AND 
CREB ANTISENSE 
  Another attempt at regulating CREB expression in brain is the 
tetracycline transactivator system, whereby doxycycline in the 
drinking water is the “switch” that is coupled to the suppression of 
transgene expression. CREB overexpression can subsequently be 
targeted to the brain, with a tetracycline transactivator (tTA) con-
trolled by a 1.8kb neuron-specific enolase (NSE) promoter. Sakai 
and colleagues [101] crossed mouse lines to generate NSE-tTA 
TetOP-CREB bi-transgenic mice, creating a system controlled by 
NSE, whose expression generates tTA, binding to the TetOP pro-
moter, generating CREB overexpression. Addition of a tetracy-
cline analogue, doxycycline, binds to a Tet binding pocket on the 
tTA, which undergoes a conformational change and binds to TetOP 
in such a way, inhibiting CREB expression. Their model demon-
strated that CREB overexpression in the brain had an inconsistent 
influence upon expression of other members of the CREB/ATF 
family (invariably downregulating though), paricularly CREM. 
CREB overexpression was restricted to the nucleus of cells, pre-
dominantly in the striatum, although with some expression ob-
served within the cingulate cortex and hippocampus. In contrast, 
Pittenger and colleagues used this model to overexpress dominant 
negative human CREB (KCREB) in either the dorsal striatum (and 
olfactory tubercle) [91] or dorsal hippocampus (CA1, and stria-
tum/piriform cortex) [92], the former demonstrating a contribution 
of CREB to procedural learning, the latter, a somewhat subtle phe-
notype in relation to spatial learning and memory. A major down-
fall of this system, however, is the time lapse (seven to fourteen 
days) required to drive corresponding alteration in gene expression, 
a critical feature regarding (m/K)CREB cytological (dys)regulation.  
  Antisense models have also been utilised, involving the local 
knockdown of CREB by infusion of CREB antisense, which binds 
to Creb mRNA thus inhibiting further translation. A small number 
of studies (Table 4) employing CREB antisense collectively dem-
onstrate the contribution of CREB to drug-induced behavioural 
phenotypeandmRNA or protein expression. Whilst antisense seems 
to provide the ‘magic bullet’ to functional gene analysis, difficulty 
with delivery systems, specificity, toxicity and inconsistent effects 
are key drivers for its limited adoption in experimentation. 
CONVENTIONAL CREB KNOCKDOWN MODELS: THE 
CONCLUSION 
  Underlying the aforementioned ‘conventional’ models of CREB 
manipulation is that while they have allowed insight, each has a 
major deficit which may confound interpretation. More recently, 
through various advances in the field of molecular biology, novel 
techniques have arisen which confer alternative targeting of the 
Creb gene and control of expression. 
LOOKING FORWARD: REGION-SPECIFIC PROMOTERS 
DRIVING SPATIOTEMPORAL CREB DELETION  
  A more recent attempt to selectively target and knockdown 
CREB from central regions involves a model of region-specific 
promoters driving the site-specific Cre  recombinase. This entails 
the cross-breeding of two strains of mice, one expressing the Cre
transgene driven by a tissue- or ontogenetic stage-specific pro-
moter, and the other a “floxed” gene (loxP sequences flanking gene 
of interest for recombination) [110]. Early problems with the model 
included the time taken to breed the strains, difficulty establishing 
well-characterised tissue-specific promoters, and the inability to 
induce Cre expression at specific ontogenetic time points [4]. Over 
time, however, the latter two have been substantially ameliorated. 
As the expression of Cre-recombinase determines the recombina-
tion event surrounding the floxed gene, numerous approaches have 
been taken in addressing its expression profile. Various region-
speicific Cre promoter models have been developed, including an 
adipose-specific aP2 enhancer/promoter [6], central- and ontoge-
netic-specific promoters CamKII [18, 19, 51], Emx-1 [21, 38, 49], 
Foxg1 [43], Nestin [5, 68], a split-polypeptide Cre construct [20], 
tyrosine hydroxylase (TH) neuronal-specific promoter [35], RSV 
Table 3.  HSV-(m)CREB Overexpression Models 
STUDY  REGION OF OVEREXPRESSION  DRUG EXPOSURE / PARA-
DIGM 
REWARD / PREFERENCE EFFECT 
[17]  NAcc Shell, Core  Cocaine CPP model  mCREB in the shell but not core increased preference; CREB in the 
shell decreased preference 
[7]  NAcc Shell  Morphine, sucrose CPP model  mCREB increased morphine and sugar (natural reward) preference; 
CREB decreased morphine and sugar preference 
[24]  Dentate gyrus (DG), CA1 pyramidal layer 
(CA1), Pre-frontal cortex (PFC) 
Antidepressents in a learned help-
lessness (LH) & Forced swim test 
(FST) model 
Not tested 
[42] Locus  Coeruleus  Precipitated morphine withdrawal 
behaviours 
Not tested 
[83]  Rostral & caudal VTA, substantia nigra  Cocaine, morphine CPP model  Rostral VTA CREB enhanced drug preference, but mCREB made 
drug aversive; caudal VTA CREB made drug aversive, but mCREB 
enhanced durg preference; CREB/mCREB in substantia nigra had no 
effect on preference; high dose morphine enhanced preference re-
gardless of CREB/mCREB injections in rostral or caudal VTA 
[93]  NAcc (shell)  Cocaine CPP model; 
Forced swim test (FST) 
mCREB increased preference, CREB decreased preference 208    Current Neuropharmacology, 2007, Vol. 5, No. 3 McPherson and Lawrence 
and EF1 promoters [32], rat insulin promoter [95, 96] and CAG 
promoter [100]. The main design behind such mutants is to induce 
disruption of all central CREB isoforms through targeting of the 
10
th Creb1 exon. Excision of exon 10 from Creb1 leads to transla-
tion of CREB deficient in DNA binding and dimerization functional 
domains, such that the protein is unstable and thus, there is loss of 
CREB [68]. The prominent applications of this technology to cellu-
lar CREB expression involves tissue-specific promoters, both re-
gional and restricted by cell-type, as well as expression of promot-
ers tied to developmental stages. Example applications of this 
model are discussed. 
NESTIN AND CAMKII DRIVEN CRE
  The nestin promoter/enhancer is associated with widespread 
central deletion of the Creb gene, as nestin expresses from embry-
onic stage in all brain regions before separation of neuronal and 
glial lineages [68], with CREB loss observed in neurons and glial 
cells. Creb1
NesCre mice nominally reach 70-80% of control mouse 
body weight from 2
nd post-natal week due to a deficiency in growth 
hormone. Data from nestin Creb-deficient mutants demonstrated no 
difference in CPP reward to morphine, cocaine or food versus wild 
type, but that they exhibited attenuated behavioural responses to 
naloxone-induced morphine withdrawal and had a heightened anx-
iogenic phenotype [112]. CaMKII is an 8.5kb promoter expressed 
in forebrain neurons from approximately P7 [5, 68] and this model 
has shown CREB loss in almost eighty percent of forebrain neu-
rons. Indeed in transgenic mice, high CamKII Cre levels have 
been demonstrated within the hippocampus, cortex, olfactory bulb 
and amygdala, and low levels in the striatum, thalamus and hypo-
thalamus. No CamKII was detected in the cerebellum [19]. In 
these mice, CREB protein began to decrease in the hippocampus 
and cortex by P6 and was observed to be totally deficient in these 
regions by P15. Together, these mice models provide a robust 
method for knockdown of all functional CREB isoforms widely 
throughout the brain at different time points, without complex de-
velopmental adaptations.  
When Applied to CREM 
  CREM deficient mutants were generated to address the question 
of what role CREM plays in the absence of CREB, given the obser-
vation that CREM may upregulate subsequent to CREB knockout. 
Mantamadiotis and colleagues [68] studied transgenic mice with 
nestin and CaMKII promoter-driven knockout of Creb1 crossed 
with Crem-deficient mice, generating pre-natal and post-natal CNS-
specific protein loss respectively. Mice with prenatal central loss of 
CREB and CREM died at P1, as they did not suckle for milk; brain 
structures in these mice were unaffected, but cell density was mark-
edly diminished, largely due to apoptosis; expected Mendelian ra-
tios were observed however. Mice with postnatal central loss of 
CREB and CREM displayed an abnormal phenotype of retraction 
of limbs when suspended for 20s, characterising a neurological 
impairment owing to neurodegeneration, and considerable progres-
sive atrophy of the dorsolateral striatum and CA1 hippocampal 
neurons; widespread astrogliosis was revealed (glial cell apoptosis) 
in dorsolateral striatum, CA1, DG and some in amygdala, cortex 
and thalamus, although a single copy of Crem prevented this (sug-
gesting accomodation for loss of CREB); expected Mendelian ra-
tios were observed. Furthermore, Crem
-/- male mutant mice are 
known to be sterile, given enhanced apoptosis of post-meioitic 
germ cells [71], although the mutation does not appear to be as 
physiologically devastating as does total CREB deletion. CREM 
null mice have been previously described [67], exhibiting hyperac-
tive and diminished anxiety-like behaviour, however, an addiction-
related phenotype remains to be characterised for this model. 
DRD1A DRIVEN Cre
  Other attempts at promoter-driven CREB deletion have aimed 
to target brain nuclei selectively, regions critical to the study of 
addiction. A D1A receptor gene promoter (Drd1a) was employed 
via 140kb YAC expression vector for Cre recombinase, generating 
a Cre expression profile predominantly constrained to the CPu, 
NAcc and OT, but with some expression observed in layer VI of the 
cortex, CA2 of the hippocampus and within thalamic nuclei. Also 
noted was neurodegeneration within the dorsolateral striatum when 
mutants were double crossed with CREM-deficient mice [68]; fur-
ther phenotypic analysis is warranted in this model.  
DARPP-32 DRIVEN Cre  
  Dopamine and cAMP-regulated phosphoprotein molecular 
weight 32 kDA (DARPP-32) bears multiple regulatory phosphory-
lation sites, and acts as an important component in the phosphoryla-
tion profile of various cytosolic and membrane-associated proteins. 
Indeed, in its activated state as pThr
34-DARPP-32, it becomes a 
robust inhibitor of protein phosphatase 1 (PP-1), a substrate respon-
Table 4.  CREB Antisense Models 
STUDY  REGION of ANTISENSE 
TARGET 
DRUG EXPOSURE / PARA-
DIGM 
GENOMIC EFFECT  PHENOTYPIC EFFECT 
[56] Striatum  Amphetamine  Antisense inhibited striatal c-fos mRNA 
unpregulation by amphetamine 
[62]   Locus coeruleus  Morphine;  
Naloxone-induced withdrawal 
Antisense blocked morphine-induced AC 
VIII and TH but not PKA type II nor Gi
upregulation 
Antisense attenuated some 
naloxone-induced withdrawal 
behaviours 
[2] Lateral  CPu  Cocaine  Antisense blocked cocaine-induced CREB, 
c-Fos, FosB, FosB and prodynorphin 
mRNA upregualtion;  
Antisense enhanced locomotor 
activity in control rats (saline) but 
didn’t change stereotypy induced 
by chronic cocaine 
[25]  NAcc core or shell (bilateral)  Cocaine  Antisense reduced regional CREB and 
BDNF expression; produced transient 
reduction in reinforcing property of co-
caine and reinforcement threshold 
[120] NAcc  (unilateral)  Cocaine 
5d injections or mini-pump infu-
sions; killed 18hr later 
CRE IR was decreased in the NAcc by 40%; a [time-dependent] reversible de-
crease in Gi and PKA-C subunit expression by 21% and 27% respectively in the 
NAcc; Attenuated c-Fos induction by acute cocaine; Didn’t affect numerous other
signal transduction pathways, including CaMKII-/, PKC-/, Go, G, PLC-
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sible for de-phosphorylation of numerous cellular targets. DARPP-
32 is highly concentrated in medium spiny neurons of the CPu and 
NAcc (neostriatal neurons), the olfactory tubercule, and lightly in 
the BNST and amygdala [40, 78]. A novel model of DARPP-32 
promoter-driven Cre [12] will provide a conduit for the selective 
knockdown of CREB, allowing the elucidation of the contribution 
of CREB within the mesolimbic system; demonstrated in Fig. (2).
Importantly, the expression of DARPP32 driven Cre in this model 
does not commence until 4-5 weeks after birth [12], ensuring a lack 
of potential developmental compensation. 
Emx1 DRIVEN Cre  
  A final model worth mentioning involves Emx1 (empty spira-
cles homologue 1), a homeobox-containing gene which is specifi-
cally expressed in the developing (from E10) telencephalic cortex 
through adulthood [49]. Emx1 is involved in encoding transcription 
factors, and found in both proliferating and post-mitotic neurons of 
the cerebral cortex, and may thus be involved in the initiation and 
maintenance of the neuronal phenotype [21]. Evidence supports its 
restriction to excitatory pyramidal neurons (layers II-VI, but not 
layer I) colocalising with glutamate (99.1%) rather than GABA 
(0.9%), as well as astrocytes and oligodentrocytes of most pallidal 
structures (vertebrate cerebral cortex primordium) including the 
hippocampus, neocortex, piriform cortex, endopiriform nucleus and 
lateral aspects of the amygdala [21, 38, 49]. Within the neocortex 
and hippocampus, approximately 88% of cells underwent recombi-
nation in total [38]. This model is important, as it allows the study 
of CREB’s contribution to corticostriatal and corticotegmental glu-
tamatergic pathways, both of which have both been strongly impli-
cated in the development of addiction related behaviours, and is 
demonstrated in Fig. (2). 
LOOKING FORWARD: REGION-SPECIFIC VIRAL VEC-
TOR KNOCKDOWN OF CREB 
  Whilst the promoter-driven strategy for central CREB deletion 
is good, some of these approaches are still germline in nature, thus 
suggestive that various difficult-to-identify compensatory adapta-
tions take place in the organism, offsetting the accuracy of experi-
mental results. Correspondingly, investigators have also turned to 
plasmid based transgene expression systems, however, these tend to 
be influenced by chromatin position effects and may result in ec-
topic or mosaic expression. Such plasmid-based transgenes, con-
taining only a few regulatory elements from the gene of interest, 
often result in unnatural configurations and generally produce 
highly variable transgene expression patterns [19]. Consequently, 
many transgenic lines need to be analysed to find one line with the 
appropriate pattern of expression. A more appropriate and attractive 
approach used by investigators is that of viral vector based Cre
delivery systems. This strategy is useful when the phenotype of the 
total knockout is lethal (embryological mutation, as is the case with 
CREB), when there are compensatory effects during development 
(in regard to other gene expression), or when total gene inactivation 
results in pleiotropic effects involving complex physiological inter-
actions. Viral-vector delivered Cre recombinase provides a spatio-
temporal model for knocking out “floxed” genes in specific nuclei 
through stereotaxic injection targeting a brain region or cell group. 
This novel approach to generating conditional knockouts has been 
validated on numerous occasions, many involving Rosa 26 Reporter 
(Rosa26) mice or -galactosidase expression systems [1, 4, 50, 89, 
119].  
EMPLOYING THE APPROPRIATE VIRUS 
  Two widely used virus strains for this purpose are the lentivirus 
and adeno-associated virus. Lentiviruses (LV) are enveloped RNA 
viruses that belong to the family of complex retroviruses. In con-
trast to prototypic retroviruses, such as murine leukemia virus, len-
tiviruses are able to transduce both dividing and nondividing cells, 
including neuronal and to a lesser extent glial (astrocyte) recombi-
nation. Adeno-associated viral (AAV) vectors induce a substan-
tially lower immunogenic dose than its predecessors, given the total 
removal of viral genome. AAV is selective toward neuronal recom-
bination in vivo, with evidence that it does not recombine in glial 
Fig. (2). CREB knockout circuitry. 
Key nuclei of the limbic circuit are demonstrated in the schematic, as well as their neurochemical projections. All regions confer a salience to 
the development of addiction, across conditioning (amygdala), learning and memory (hippocampus) and reward and reinforcement (NAcc, 
VTA, PFC). As mentioned in the main text, Emx1-driven Cre would knockout CREB from the regions indicated, although a major knock-
down should be observed in the PFC, thus impacting upon glutamatergic projections to the NAcc and VTA. DARPP-32-driven Cre would
knockout CREB from MSNs of the NAcc, allowing us to address the impact upon striatal outflow. Viral vector strategies could allow the 
specific knockdown of CREB from individual nuclei listed on the schematic. Abbreviations: Amyg, amygdala; Hip, hippocampus; NAcc,
nucleus accumbens; PFC, prefrontal cortex; VTA, ventral tegmental area. 210    Current Neuropharmacology, 2007, Vol. 5, No. 3 McPherson and Lawrence 
cells [50]. Optimal expression is usually 2-4 weeks following injec-
tion. Given that AAV and LV are useful in mediating gene delivery 
and stable transduction to both dividing and non-dividing cells, 
whilst not inducing an immune response, they provide a valuable 
role in CNS recombination. AAV vectors are typically limited to 
accepting only short inserts of up to 5kb [1], however a high capac-
ity adenoviral vector expressing Cre recombinase has been de-
scribed [4]. In this case, all viral coding sequences have been de-
leted from the viral genome, reducing the expression vector’s toxic-
ity and immunogenicity, whilst increasing the capacity for introduc-
tion of heterologous DNA to 36kB, facilitating increased flexibility. 
Viral-delivered  Cre can be toxic, likely owing to mammalian 
pseudo-loxP sequence homology [1, 89], where heightened Cre can
reduce proliferation [107], induce chromosomal abberation and 
exchanges with sister chromatids [64], and cause neural (brain) 
cavities. Chronic high-level expression of Cre  in spermatids of 
transgenic mice has also been demonstrated to generate male steril-
ity [102]. This has been addressed by using lower Cre doses, whilst 
still achieving substantial recombination [1], or use of self-deleting 
viral vectors. The latter has been pioneered with lentiviral delivery 
of Cre, such that the U3 untranslated region (3’ LTR) of the LV 
vector has a Cre insert which expresses only once incorporated into 
the mammalian genome, self-removing from the genome as Cre
concentration rises [89, 107]. In the context of the study of addic-
tion, application of this model to selectively target brain regions 
critical to the development of addiction will prove valuable in de-
termining the contribution of CREB to various pathways of the 
midbrain and forebrain. 
FUTURE CREB KNOCKDOWN MODELS: THE CONCLU-
SION 
  These spatiotemporal paradigms are important indeed, critical, 
to more efficacious targeting of CREB knockdown in specific cells 
as well as nuclei. This can better assist in diagnosis of the diverse 
role CREB plays in neuronal signalling, contributing to addictive 
behaviours and / or how this phenotype relates to molecular signal-
ling pathways, when both are used in unison. As these models are 
more widely adopted over subsequent years, the data on the contri-
bution of CREB to the development and expression of addiction 
should be more reliable, and help us better understand its biological 
function. 
CONCLUSIONS 
  This review has briefly discussed the relevance of CREB as a 
critical biological substrate for the development of addiction, and 
examined a variety of drug contexts and paradigms with wild type 
subjects demonstrating its diverse and complex expression pattern. 
Earlier models, which endeavoured to remove peripheral or central 
CREB isoforms to determine its impact upon addiction more 
closely, were found to be in various ways deficient and inadequate 
for robust and consistent reporting. More recently, spatiotemporal 
CREB deletion models have provided an illuminating and exciting 
way forward for the study of total central CREB deletion both tem-
porally, and spatially within the brain, allowing investigators to 
better characterise precisely the contribution of CREB to the devel-
opment and / or persistence of the addicted state. 
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ABBREVIATIONS 
ATF-1  =  Activating transcription factor-1 
CaMK =  Ca
2+/calmodulin protein kinase 
CREB  =  cAMP responsive element binding protein 
CREM  =  cAMP responsive element modulatory protein 
LC =  Locus  coeruleus 
METH =  Methamphetamine 
NAcc = Nucleus  accumbens 
PDE =  Phosphodiesterase 
PVN  =  paraventricular nucleus of the hypothalamus; 
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